New Evidence Available
Updated Recommendation
A new evidence synthesis was published:2022, Updated recommendations on treatment of adolescents and children with chronic HCV infection: policy brief.
View latest version (2022)Bibliographic Info
GuidelineGuidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection
Year of Publication2018
Issuing InstitutionWorld Health Organization
Recommendation
Status
Retired
Recommended in favor
Strong
Certainty of evidence
Very low
In adolescents aged 12–17 years or weighing at least 35 kg with chronic HCV, WHO recommends sofosbuvir/ribavirin for 12 weeks in genotype 2